Study of Treating Cirrhosis with Portal Hypertension in Rat Model by Portal Targeting Infusion of DDPH via Different Routes

Objective To find out the appropriate routes for portal targeting infusion in treating portal hypertension.Materials and Methods Twenty eight cirrhotic rat models with portal hypertension induced by CCl 4 were divided into 4 groups, each group was injected with DDPH [1 (2,6 dimethylphenoxy) 2 (3,4 dime thoxyphenylamino) propane hydrochloride] via IVC, portal vein, hepatic artery or spleen respectively. The changes in portal vein pressure (PVP), IVC pressure (IVCP), mean artery pressure (MAP) and heart rate (HR) were observed and compared between each group.Results DDPH intraportal or hepatic artery injection induced a bigger drop in PVP and showed less effects on MAP and HR than intravenous injection did. A significant bigger drop in PVP CVP was seen in group via spleen administration than that in group via intravenous injection, although no difference in PVP decrease rate between intravenous injection and spleen injection was found.Conclusion For the treatment of portal hypertension, hepatic artery DDPH administration carries the same advantages as intraportal infusion has, i.e. a greater decrease in PVP, less effect on systemic hemodynamics. Hepatic artery infusion of vasodilation drugs via percutaneous port catheter system implanted in hepatic artery may be an ideal method for the treatment of portal hypertension.